(Total Views: 273)
Posted On: 09/12/2017 9:07:01 AM
Post# of 72446
More from the swamp:
georgejjl Tuesday, 09/12/17 07:49:51 AM
Re: None
Post #
196509
of 196512 Go
This available funding allows Innovation Pharmaceuticals to negotiate from a position of financial strength. It allows them to walk away from a deal that is not high enough. Negotiations go better when the seller sees a fair price and the buyer offers a fair price.
Innovation Pharmaceuticals is not committed to take any of this funding if the right deal with a fair multi-billion dollar offer is made before the funds are needed.
Quote:
“For many years now, Aspire has been a tremendous institutional investor and financial partner to our Company and many of our successes to date are underscored by their unwavering support,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Aspire’s new $30 million commitment combined with our cash on hand puts us in a strong financial position to continue our aggressive drug development strategies.”
Separately, the Company has filed all requisite documentation with the U.S. Securities and Exchange Commission (“SEC”) as part of a $75 million shelf registration.
$30 million plus $75 million= $105 million available in necessary.
Negotiate with big pharmaceuticals from a position of financial strength.
https://globenewswire.com/news-release/2017/0...ement.html
https://www.sec.gov/Archives/edgar/data/13552...pix_s3.htm
Good luck and GOD bless,
George
georgejjl Tuesday, 09/12/17 07:49:51 AM
Re: None
Post #
196509
of 196512 Go
This available funding allows Innovation Pharmaceuticals to negotiate from a position of financial strength. It allows them to walk away from a deal that is not high enough. Negotiations go better when the seller sees a fair price and the buyer offers a fair price.
Innovation Pharmaceuticals is not committed to take any of this funding if the right deal with a fair multi-billion dollar offer is made before the funds are needed.
Quote:
“For many years now, Aspire has been a tremendous institutional investor and financial partner to our Company and many of our successes to date are underscored by their unwavering support,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Aspire’s new $30 million commitment combined with our cash on hand puts us in a strong financial position to continue our aggressive drug development strategies.”
Separately, the Company has filed all requisite documentation with the U.S. Securities and Exchange Commission (“SEC”) as part of a $75 million shelf registration.
$30 million plus $75 million= $105 million available in necessary.
Negotiate with big pharmaceuticals from a position of financial strength.
https://globenewswire.com/news-release/2017/0...ement.html
https://www.sec.gov/Archives/edgar/data/13552...pix_s3.htm
Good luck and GOD bless,
George
(0)
(0)
